Related Experiment Video

Updated: Jun 12, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.1K

PROSTACYCLIN-ANALOG THERAPY FOR PULMONARY VASCULAR DYSFUNCTION DURING SEVERE ACUTE CHEST SYNDROME IN SICKLE CELL

Julien Lopinto, Elsa Moncomble, Ségolène Gendreau

    Shock (Augusta, Ga.)
    |April 23, 2025
    PubMed

    Keywords:
    ACP — acute core pulmonaleACS — acute chest syndromeARDS — acute respiratory distress syndromeDHTR — delayed hemolytic transfusion reactionEDEI — end-diastolic eccentricity indexESEI — end-systolic eccentricity indexICU — intensive care unitIQR — interquartile rangePASP — pulmonary artery systolic pressurePGI2 — prostacyclinSAPS II — Simplified Acute Physiology Score IISCD — sickle cell diseaseSD — standard deviationSickle cell diseaseTAPSE — tricuspid annular plane systolic excursionTRV — tricuspid regurgitant jet velocityVOC — vaso-occlusive crisisacute chest syndrome, acute cor pulmonaleepoprostenoliNO — inhaled nitric oxidepulmonary vascular dysfunction

    More Related Videos

    Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging10:50

    Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

    Published on: June 29, 2013

    12.3K
    Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

    Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

    Published on: June 12, 2021

    3.2K

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    159
    Peripheral Artery Disease III: Interprofessional Care01:27

    Peripheral Artery Disease III: Interprofessional Care

    Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
    3
    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

    Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
    3
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    3
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    134
    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

    Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

    Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
    Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
    496